<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer New York</PublisherName>
    <PublisherLocation>New York, NY</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
  </PublisherInfo>
  <Book Language="En">
    <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
      <BookID>978-1-60327-829-4</BookID>
      <BookTitle>Drug Management of Prostate Cancer</BookTitle>
      <BookDOI>10.1007/978-1-60327-829-4</BookDOI>
      <BookTitleID>158057</BookTitleID>
      <BookPrintISBN>978-1-60327-831-7</BookPrintISBN>
      <BookElectronicISBN>978-1-60327-829-4</BookElectronicISBN>
      <BookChapterCount>37</BookChapterCount>
      <BookCopyright>
        <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
        <CopyrightYear>2010</CopyrightYear>
      </BookCopyright>
      <BookSubjectGroup>
        <BookSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</BookSubject>
        <BookSubject Code="SCH33160" Priority="1" Type="Secondary">Oncology</BookSubject>
        <BookSubject Code="SCH62002" Priority="2" Type="Secondary">Urology</BookSubject>
        <BookSubject Code="SCH33002" Priority="3" Type="Secondary">Internal Medicine</BookSubject>
        <SubjectCollection Code="SUCO11650">Medicine</SubjectCollection>
      </BookSubjectGroup>
    </BookInfo>
    <BookHeader>
      <EditorGroup>
        <Editor AffiliationIDS="AffID1">
          <EditorName DisplayOrder="Western">
            <GivenName>William D.</GivenName>
            <FamilyName>Figg</FamilyName>
          </EditorName>
          <Contact>
            <Phone>301402-3622</Phone>
            <Fax>301402-8606</Fax>
            <Email>wdfigg@helix.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID2">
          <EditorName DisplayOrder="Western">
            <GivenName>Cindy H.</GivenName>
            <FamilyName>Chau</FamilyName>
          </EditorName>
          <Contact>
            <Email>chauc@mail.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID3">
          <EditorName DisplayOrder="Western">
            <GivenName>Eric J.</GivenName>
            <FamilyName>Small</FamilyName>
          </EditorName>
          <Contact>
            <Phone>415/353-7171</Phone>
            <Email>smalle@medicine.ucsf.edu</Email>
          </Contact>
        </Editor>
        <Affiliation ID="AffID1">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID2">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID3">
          <OrgDivision>School of Medicine, Dept. Urology</OrgDivision>
          <OrgName>University of California, San Francisco</OrgName>
          <OrgAddress>
            <Street>Divisadero Street 1600</Street>
            <City>San Francisco</City>
            <Postcode>94115</Postcode>
            <State>California</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </BookHeader>
    <Part ID="Part6">
      <PartInfo OutputMedium="All" TocLevels="0">
        <PartID>6</PartID>
        <PartNumber>Part V</PartNumber>
        <PartSequenceNumber>6</PartSequenceNumber>
        <PartTitle>Immunotherapy</PartTitle>
        <PartChapterCount>4</PartChapterCount>
        <PartContext>
          <BookID>978-1-60327-829-4</BookID>
          <BookTitle>Drug Management of Prostate Cancer</BookTitle>
        </PartContext>
      </PartInfo>
      <Chapter ID="Chap28" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
          <ChapterID>28</ChapterID>
          <ChapterNumber>Chapter 28</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-829-4_28</ChapterDOI>
          <ChapterSequenceNumber>28</ChapterSequenceNumber>
          <ChapterTitle Language="En">Sipuleucel-T: Autologous Cellular Immunotherapy for Metastatic Castration-Resistant Prostate Cancer</ChapterTitle>
          <ChapterFirstPage>321</ChapterFirstPage>
          <ChapterLastPage>328</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2010</CopyrightYear>
          </ChapterCopyright>
          <ChapterHistory>
            <RegistrationDate>
              <Year>2010</Year>
              <Month>4</Month>
              <Day>16</Day>
            </RegistrationDate>
            <OnlineDate>
              <Year>2010</Year>
              <Month>8</Month>
              <Day>3</Day>
            </OnlineDate>
          </ChapterHistory>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <PartID>6</PartID>
            <BookID>978-1-60327-829-4</BookID>
            <BookTitle>Drug Management of Prostate Cancer</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author AffiliationIDS="Aff1_28" CorrespondingAffiliationID="Aff1_28">
              <AuthorName DisplayOrder="Western">
                <GivenName>Celestia</GivenName>
                <GivenName>S.</GivenName>
                <FamilyName>Higano</FamilyName>
              </AuthorName>
              <Contact>
                <Email>thigano@u.washington.edu</Email>
              </Contact>
            </Author>
            <Affiliation ID="Aff1_28">
              <OrgDivision>Seattle Cancer Care Alliance</OrgDivision>
              <OrgName>University of Washington</OrgName>
              <OrgAddress>
                <City>Seattle</City>
                <State>WA</State>
                <Country>USA</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1_28" Language="En" OutputMedium="All">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">Few treatment options are currently available for patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (CRPC). Second line hormonal approaches are effective for a median of 3 months’ time but have never been shown to prolong survival. Until recently, docetaxel was the only FDA-approved therapy for mCRPC that has been shown to extend survival. Sipuleucel-T is an autologous cellular immunotherapy treatment. In an initial Phase 3 study, a significant effect on the primary endpoint of time to disease progression was not demonstrated, but a 4.5-month improvement in median survival compared to control was observed. A subsequent phase III study of sipuleucel-T in 512 men with asymptomatic or minimally symptomatic CRPC, resulted in a 4.1-month improvement in median survival compared to control. The most common adverse events observed in sipuleucel-T treated patients in randomized trials have been chills, fatigue, fever, back pain, nausea, joint ache, and headache. The survival benefit, adverse event profile, and short course of treatment (4 weeks) associated with sipuleucel-T therapy make it an appealing treatment option for asymptomatic metastatic castrate resistant prostate cancer patients.</Para>
          </Abstract>
          <KeywordGroup Language="En" OutputMedium="All">
            <Heading>Keywords</Heading>
            <Keyword>Autologous cellular immunotherapy</Keyword>
            <Keyword>Castration-resistant</Keyword>
            <Keyword>APC8015</Keyword>
            <Keyword>Hormone refractory</Keyword>
            <Keyword>Immunotherapy</Keyword>
            <Keyword>Prostate cancer</Keyword>
            <Keyword>Provenge</Keyword>
            <Keyword>Sipuleucel-T</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1" Type="Introduction">
            <Heading>Introduction</Heading>
            <Para TextBreak="No">In 2009, prostate cancer is expected to claim the lives of 27,360 men in the USA, a statistic that is essentially unchanged from 1989 despite continued refinements in detection and treatment of this disease [<CitationRef CitationID="CR1_28">1</CitationRef>]. Each year brings the diagnosis of more than 192,000 new cases of prostate cancer, the second most common cause of cancer death in males [<CitationRef CitationID="CR1_28">1</CitationRef>]. As depicted in Fig. <InternalRef RefID="Fig1">28.1</InternalRef>, first-line treatment for localized disease may consist of radical prostatectomy and/or radiation therapy [<CitationRef CitationID="CR2_28">2</CitationRef>]. If disease recurs, typically manifested by a rising prostate-specific antigen (PSA) without evidence of metastases on imaging studies, androgen deprivation may be initiated, either by orchiectomy or hormonal therapy with luteinizing hormone-releasing hormone agonists. Given sufficient time, most patients with hormone sensitive non-metastatic disease will progress to castration-resistant metastatic disease despite androgen deprivation. <Figure Category="Standard" Float="Yes" ID="Fig1">
                <Caption Language="En">
                  <CaptionNumber>Fig. 28.1</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>Natural history of prostate cancer and common treatment options with proposed use of immunotherapy</SimplePara>
                  </CaptionContent>
                </Caption>
                <MediaObject ID="MO1_28">
                  <ImageObject Color="Color" FileRef="MediaObjects/978-1-60327-829-4_28_Fig1_HTML.gif" Format="GIF" Rendition="HTML" Type="Linedraw"/>
                </MediaObject>
              </Figure>
            </Para>
            <Para TextBreak="No">Docetaxel (Taxotere<Superscript>®</Superscript>, Sanofi-Aventis, NY) is the first Food and Drug Administration (FDA)-approved agent to demonstrate a significant survival advantage in metastatic CRPC [<CitationRef CitationID="CR3_28">3</CitationRef>]. In the TAX327 study by Tannock and colleagues that formed the basis for approval [<CitationRef CitationID="CR4_28">4</CitationRef>], treatment with docetaxel and prednisone in a mixed population of symptomatic and asymptomatic patients resulted in a median survival benefit of 2.4 months when compared to mitoxantrone and prednisone. Serious adverse events were observed in 26% of patients. A supporting phase III trial of docetaxel and estramustine (Emcyt<Superscript>®</Superscript>, Pfizer, Inc, New York, NY) also demonstrated a median survival increase of 1.9 months compared to mitoxantrone and prednisone. Grade 3–5 toxicities were observed in 56% of patients [<CitationRef CitationID="CR5_28">5</CitationRef>].</Para>
            <Para TextBreak="No">Due to the toxicities of chemotherapy, many men with metastatic CRPC who do not have significant symptoms choose to delay or forgo chemotherapy despite the demonstration of survival benefit [<CitationRef CitationID="CR7_28">7</CitationRef>], particularly given that there is no evidence that delaying administration of docetaxel is detrimental [<CitationRef CitationID="CR6_28">6</CitationRef>]. Men who have no or minimal symptoms due to metastatic CRCP make good subjects for the study of new agents with minimal toxicity. With respect to immunological approaches, this population is appropriate since it may take weeks to months for an immune response to be mounted.</Para>
            <Para TextBreak="No">Several immunologic approaches to prostate cancer are being studied [<CitationRef CitationID="CR8_28">8</CitationRef>]. Recently, Sipuleucel-T (Provenge<Superscript>®</Superscript>, APC8015; Dendreon Corporation, Seattle, WA, USA) an autologous cellular immunotherapy designed to treat prostate cancer, was approved by the FDA in April 2010 based on the results of a phase III trial in men with metastatic CRPC who had no or minimal symptoms [<CitationRef CitationID="CR9_28">9</CitationRef>]. Other active immunotherapy approaches for the treatment of prostate cancer include Prostvac VF (Bavarian Nordic, Kvistgaard, Denmark), a live attenuated virus encoding PSA and co-stimulatory molecules, and GVAX (BioSante Pharmaceuticals, Lincolnshire, IL), prostate cancer cell lines transfected with granulocyte macrophage-colony stimulating factor (GM-CSF) (see <ExternalRef>
                <RefSource>Chapter 29</RefSource>
                <RefTarget Address="10.1007/978-1-60327-829-4_29" TargetType="DOI"/>
              </ExternalRef> on GVAX). This chapter will address the most recent clinical data on sipuleucel-T.</Para>
          </Section1>
          <Section1 ID="Sec2">
            <Heading>Sipuleucel-T Cellular Immunotherapy</Heading>
            <Para TextBreak="No">Sipuleucel-T is an FDA approved autologous cellular immunotherapy product for the treatment of prostate cancer. Sipuleucel-T is an active immunotherapy which is dependent upon the effective presentation of a suitable target antigen to the immune system by antigen-presenting cells (APC). The sipuleucel-T product consists of autologous APCs loaded with a recombinant prostate antigen protein, PA2024, designed to stimulate a patient’s own immunity to prostate cancer. PA2024 is a fusion protein composed of prostatic acid phosphatase (PAP) linked to GM-CSF. PAP is a prostate antigen that is expressed in more than 95% of prostate adenocarcinomas [<CitationRef CitationID="CR10_28">10</CitationRef>, <CitationRef CitationID="CR11_28">11</CitationRef>] and has been shown to be an effective target antigen in experimental animal models [<CitationRef CitationID="CR12_28">12</CitationRef>, <CitationRef CitationID="CR13_28">13</CitationRef>].</Para>
            <Para TextBreak="No">Preparation of sipuleucel-T involves harvesting peripheral blood mononuclear cells and loading them ex vivo with the PA2024 antigen (Fig. <InternalRef RefID="Fig2">28.2</InternalRef>). The peripheral blood mononuclear cells include a large number of autologous APCs, in the range of 10<Superscript>8</Superscript>–10<Superscript>9</Superscript> cells [<CitationRef CitationID="CR14_28">14</CitationRef>]. The ex vivo manufacturing process removes the APCs from the potentially immunosuppressive environment found in patients with advanced cancer and directly exposes them to PAP antigen, theoretically allowing for a more robust immune activation [<CitationRef CitationID="CR15_28">15</CitationRef>, <CitationRef CitationID="CR16_28">16</CitationRef>]. Although the precise mechanism of action of sipuleucel-T is unknown, the activated autologous APCs that are infused back into the patient are thought to stimulate the immune system to attack and kill tumor cells.<Figure Category="Standard" Float="Yes" ID="Fig2">
                <Caption Language="En">
                  <CaptionNumber>Fig. 28.2</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>Production of sipuleucel-T and its proposed mechanism of action for its effect on prostate cancer cells. A full course of therapy consists of a total of three leukapheresis procedures and product infusions, one each at weeks 0, 2, and 4</SimplePara>
                  </CaptionContent>
                </Caption>
                <MediaObject ID="MO2_28">
                  <ImageObject Color="Color" FileRef="MediaObjects/978-1-60327-829-4_28_Fig2_HTML.gif" Format="GIF" Rendition="HTML" Type="Linedraw"/>
                </MediaObject>
              </Figure>
            </Para>
            <Para TextBreak="No">Each lot of sipuleucel-T is prepared from the patient’s own peripheral blood mononuclear cells obtained via a standard 1.5–2.0 blood volume leukapheresis procedure as illustrated in Fig. <InternalRef RefID="Fig2">28.2</InternalRef>. Autologous APCs are cultured ex vivo with PA2024 for approximately 40 h. Cells are washed, and the final cellular product is suspended in lactated ringer’s solution and delivered for infusion approximately 3 days after completion of the leukapheresis. Sipuleucel-T is produced and administered intravenously at approximately weeks 0, 2, and 4.</Para>
          </Section1>
          <Section1 ID="Sec3">
            <Heading>Clinical Efficacy of Sipuleucel-T</Heading>
            <Section2 ID="Sec4">
              <Heading>
                <Emphasis Type="BoldItalic">Phase I/II Studies</Emphasis>
              </Heading>
              <Para TextBreak="No">Eight phase I/II studies (Table <InternalRef RefID="Tab1">28.1</InternalRef>) have been conducted in 223 prostate cancer patients to evaluate safety and to explore dosing regimens for sipuleucel-T [<CitationRef CitationID="CR14_28">14</CitationRef>, <CitationRef CitationID="CR17_28">17</CitationRef>–<CitationRef CitationID="CR22_28">22</CitationRef>]. Most were monotherapy treatments in CRPC, with the exception of the study by Beinart et al. [<CitationRef CitationID="CR20_28">20</CitationRef>] which evaluated sipulecuel-T in men with a rising PSA following definitive local therapy, and the study by Rini et al. [<CitationRef CitationID="CR21_28">21</CitationRef>] that evaluated sipuleucel-T in combination with bevacizumab in 22 androgen-sensitive prostate cancer patients with nonmetastatic, recurrent disease manifested by a rising PSA following definitive local therapy.<Table Float="Yes" ID="Tab1">
                  <Caption Language="En">
                    <CaptionNumber>Table 28.1</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Clinical studies with sipuleucel-T in prostate cancer</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <tgroup cols="6">
                    <colspec colname="c1" colnum="1"/>
                    <colspec colname="c2" colnum="2"/>
                    <colspec colname="c3" colnum="3"/>
                    <colspec colname="c4" colnum="4"/>
                    <colspec colname="c5" colnum="5"/>
                    <colspec colname="c6" colnum="6"/>
                    <thead>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Study</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Phase</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Description</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>
                            <Emphasis Type="Italic">N</Emphasis>
                          </SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>Patient population</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>References</SimplePara>
                        </entry>
                      </row>
                    </thead>
                    <tbody>
                      <row>
                        <entry nameend="c6" namest="c1">
                          <SimplePara>Studies with sipuleucel-T in castration-resistant prostate cancer</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>D9610</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>I/II</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Dose escalation, safety</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>31</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>Metastatic and nonmetastatic</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Small et al. [<CitationRef CitationID="CR14_28">14</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>D9702</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>I/II</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Dose escalation, safety</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>34</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>Metastatic</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Burch et al. [<CitationRef CitationID="CR18_28">18</CitationRef>
                            <CitationRef CitationID="CR19_28">, 19</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>D9801</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>I</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Dose–response</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>15</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>Metastatic and nonmetastatic</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Data on file<Superscript>a</Superscript>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>D9906</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>I</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Dose–response</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>18</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>Metastatic and nonmetastatic</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Takaue et al.[<CitationRef CitationID="CR17_28">17</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>D9903</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>II</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Cryopreserved product</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>56<Superscript>b</Superscript>
                          </SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>Asymptomatic metastatic</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Data on file<Superscript>a</Superscript>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>PB01</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>II</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Cryopreserved product</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>28<Superscript>c</Superscript>
                          </SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>Asymptomatic metastatic</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Data on file<Superscript>a</Superscript>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>D9901</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>III</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Safety and efficacy</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>127</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>Asymptomatic metastatic</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Small et al. [<CitationRef CitationID="CR9_28">9</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>D9902A</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>III</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Safety and efficacy</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>98</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>Asymptomatic metastatic</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Higano et al. [<CitationRef CitationID="CR22_28">22</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>D9902B<Superscript>c</Superscript>
                          </SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>III</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Safety and efficacy</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>512</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>Asymptomatic/minimally symptomatic</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Kantoff et al. [<CitationRef CitationID="CR23_28">23</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry nameend="c6" namest="c1">
                          <SimplePara>Studies with sipuleucel-T in nonmetastatic castration-sensitive prostate cancer</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>D9905</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>II</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Safety</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>19</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>Rising PSA after definitive local therapy</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Beinart et al. [<CitationRef CitationID="CR20_28">20</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>P-16</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>II</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Sipuleucel-T + bevacizumab</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>22</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>Rising PSA after definitive local therapy</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Rini et al. [<CitationRef CitationID="CR21_28">21</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>P-11</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>III</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Safety and efficacy</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>176</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>Rising PSA after radical prostatectomy and 3 months of hormonal therapy</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Beer et al. [<CitationRef CitationID="CR24_28">24</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                    </tbody>
                  </tgroup>
                  <tfooter>
                    <SimplePara>
                      <Superscript>a</Superscript>Dendreon Corporation, Seattle, WA</SimplePara>
                    <SimplePara>
                      <Superscript>b</Superscript>Also enrolled in D9902A</SimplePara>
                    <SimplePara>
                      <Superscript>c</Superscript>Also enrolled in D9902B</SimplePara>
                  </tfooter>
                </Table>
              </Para>
              <Para TextBreak="No">The ability of sipuleucel-T to stimulate an immune response was measured in several studies by T-cell proliferation and/or interferon-gamma enzyme-linked immunospot (ELISPOT) assay. In each of these studies, T-cell stimulation by the immunizing antigen was observed in 90–100% of patients treated with sipuleucel-T [<CitationRef CitationID="CR14_28">14</CitationRef>, <CitationRef CitationID="CR17_28">17</CitationRef>, <CitationRef CitationID="CR21_28">21</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec5">
              <Heading>
                <Emphasis Type="BoldItalic">Completed Phase III Clinical Studies in CRPC</Emphasis>
              </Heading>
              <Para TextBreak="No">Completed phase III clinical studies of sipuleucel-T in metastatic CRPC involved treatment of a total of 737 patients in three trials (Table <InternalRef RefID="Tab1">28.1</InternalRef>). D9901 and D9902A were identically designed, prospective, multicenter, randomized, double-blind, controlled studies in men with asymptomatic metastatic CRPC. The primary endpoint for these studies was time to disease progression (TTP), and a prespecified analysis of overall survival was to be performed after 36 months of follow-up. D9902B was a prospective, randomized, double blind, multi-center, controlled trial in men with symptomatic or minimally symptomatic metastatic CRPC. The primary efficacy endpoint for D9902B was overall survival.</Para>
            </Section2>
            <Section2 ID="Sec6">
              <Heading>
                <Emphasis Type="BoldItalic">D9901 Study</Emphasis>
              </Heading>
              <Para TextBreak="No">The D9901 (NCT00005947) study used a 2:1 enrollment scheme with 82 patients randomized to control consisting of mononuclear cells cultured without antigen; all 127 patients were included in the intent-to-treat (ITT) population. The primary endpoint was TTP on the basis of bone scan, computed tomography, or clinical events associated with progression. There was a 31% reduction in the risk of disease progression (<Emphasis Type="Italic">p</Emphasis> = 0.052; log-rank; hazard ratio (HR) 0.69). The median TTP was 11.7 and 10.0 weeks in the treated and control groups, respectively [<CitationRef CitationID="CR9_28">9</CitationRef>]. In a 3-year ITT analysis, patients randomized to sipuleucel-T demonstrated a 41% decrease in the risk of death (<Emphasis Type="Italic">p</Emphasis> = 0.010, log-rank; HR 0.58). The median overall survival was 25.9 months in the sipuleucel-T arm compared to 21.4 months for patients in the control arm (Fig. <InternalRef RefID="Fig3">28.3</InternalRef>), a 4.5-month improvement. In addition, 34% of patients receiving sipuleucel-T were alive at 36 months compared to 11% of patients receiving control (<Emphasis Type="Italic">p</Emphasis> = 0.005) (see Fig. <InternalRef RefID="Fig3">28.3</InternalRef>). Finally, the treatment effect remained after adjustment for baseline prognostic factors (lactate dehydrogenase, PSA, number of bone metastases, body weight, and localization of disease.<Figure Category="Standard" Float="Yes" ID="Fig3">
                  <Caption Language="En">
                    <CaptionNumber>Fig. 28.3</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Overall Kaplan–Meier survival benefit from treatment with sipuleucel-T in the D9901 study. From Small et al. [<CitationRef CitationID="CR11_28">9</CitationRef>]. Reprinted with permission. ©2008 American Society of Clinical Oncology. All rights reserved</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <MediaObject ID="MO3_28">
                    <ImageObject Color="Color" FileRef="MediaObjects/978-1-60327-829-4_28_Fig3_HTML.gif" Format="GIF" Rendition="HTML" Type="Linedraw"/>
                  </MediaObject>
                </Figure>
              </Para>
              <Para TextBreak="No">Approximately 60% of these patients were subsequently treated with chemotherapy and similar numbers of each group (37% in the sipuleucel-T group and 49% in the control group) were treated specifically with docetaxel [<CitationRef CitationID="CR9_28">9</CitationRef>]. In addition, there was no evidence of a difference in the time to initiation of chemotherapy between the treatment arms, and the sipuleucel-T treatment effect persisted following adjustment for docetaxel use. Thus, the survival benefit observed in this study was not likely attributable to docetaxel or other subsequent chemotherapy.</Para>
              <Para TextBreak="No">A subset of patients in the D9901 study was assessed for immunological response to PA2024. Patients treated with sipuleucel-T treatment had an eightfold increase in T-cell stimulation to the immunizing antigen (<Emphasis Type="Italic">p</Emphasis> &lt; 0.001, Wilcoxon rank sum) compared to their baseline values [<CitationRef CitationID="CR9_28">9</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec7">
              <Heading>
                <Emphasis Type="BoldItalic">D9902A Study</Emphasis>
              </Heading>
              <Para TextBreak="No">The D9902 study was identical in original design to the D9901 study. Based on the initial disease progression results from D9901, and prior to the availability of the overall survival results from D9901, enrollment in D9902 was halted at 98 patients (65 treated with sipuleucel-T and 33 treated with control). The study was renamed D9902A. There was no difference in TTP between the treatment arms. There was a 21% reduction in the risk of death for sipuleucel-T-treated patients relative to control, which was not statistically significant (<Emphasis Type="Italic">p</Emphasis> = 0.331, log-rank; HR 0.79). The median survival was 19.0 months in the sipuleucel-T arm compared to 15.7 months in the control arm. The treatment effect remained after adjustment for baseline prognostic factors using an exploratory Cox multiple regression model developed on the D9901 data [<CitationRef CitationID="CR22_28">22</CitationRef>]. At 36 months post randomization, 32% of the sipuleucel-T patients in D9902A were alive compared to 21% of the control-treated patients.</Para>
              <Para TextBreak="No">An exploratory integrated analysis of the data from D9901 and D9902A was performed based on the identical trial designs, eligibility criteria, and consistent treatment effects observed in the two studies. In this analysis, the reduction in the risk of death and survival benefit were maintained [<CitationRef CitationID="CR22_28">22</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec8">
              <Heading>
                <Emphasis Type="BoldItalic">D9902B Study</Emphasis>
              </Heading>
              <Para TextBreak="No">The D9902B (NCT00065442) study used a 2:1 enrollment scheme, with 341 patients randomized to sipuleucel-T and 171 patients randomized to control; all 512 patients were included in the ITT population. The primary efficacy endpoint in D9902B was overall survival and the secondary efficacy endpoint was TTP by independent assessment of serial imaging studies. There was a 22.5% reduction in the risk of death (o=0.032; HR 0.775;) and a 4.1 month improvement in median survival (25.8 months for sipuleucel-T vs. 21.7 months for control) [<CitationRef CitationID="CR23_28">23</CitationRef>]. The median time to objective disease progression was 14.6 weeks (3.7 months) in the sipuleucel-T group and 14.4 weeks (3.6 months in the control (p=0.628; HR 0.951). In addition, 31.7% of patients receiving sipuleucel-T were alive at 36 months compared to 23.0% of patients for control. The treatment effect consistently favored the sipuleucel-T group in patient subgroups based on 20 baseline characteristics of the patients. The treatment effect was observed after adjustment for the presence or absence of docetaxel after sipuleucel-T (p=0.03; HR 0.78). Therapy with sipuleucel-T was also associated with a positive overall survival effect in an analysis that included 18 additional deaths observed between the data-cutoff and study-completion dates, with a median of 36.5 months of follow-up (p=0.02; HR 0.76). Adverse events reported more frequently in the patients who received sipuleucel-T included chills, fever, and headache [<CitationRef CitationID="CR23_28">23</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec9">
              <Heading>
                <Emphasis Type="BoldItalic">Developmental History of Sipuleucel-T in Metastatic CRPC</Emphasis>
              </Heading>
              <Para TextBreak="No">The original intent of the phase III studies, D9901 and D9902, was to evaluate the ability of sipuleucel-T to delay disease progression (TTP), the primary endpoint, in patients with asymptomatic metastatic CRPC. Additionally, there was a prespecified plan to analyze survival after all patients were followed for 36 months postrandomization. In 2002, when the primary analysis for study D9901 was performed, the disease progression endpoint was not met. Based on this result, D9902 enrollment was stopped early. The study remained blinded and was renamed D9902A. All subjects in both studies D9901 and D9902A continued to be followed for survival. From the knowledge gained in the analysis of D9901, a new phase III study was designed, D9902B, under a Special Protocol Assessment with the FDA. Following the availability of the overall survival results from D9901 and D9902A, a Biologics License Application was filed in 2006. In May 2007, the FDA requested additional clinical data from the D9902B trial prior to licensure of sipuleucel-T. In November 2009, Dendreon filed a supplement to the Biologics License Application and received approval for licensure of sipuleucel-T by the FDA in April 2010 for the treatment of asymptomatic or minimally symptomatic metastatic CRPC.</Para>
            </Section2>
            <Section2 ID="Sec10">
              <Heading>
                <Emphasis Type="BoldItalic">Ongoing Randomized Study</Emphasis>
              </Heading>
              <Para TextBreak="No">One additional randomized study, P-11 is currently ongoing (Table <InternalRef RefID="Tab1">28.1</InternalRef>). P-11 is a study of hormone-sensitive patients with nonmetastatic prostate cancer who experienced PSA elevation following radical prostatectomy [<CitationRef CitationID="CR24_28">24</CitationRef>]. P-11 has reached the enrollment goal and is closed to accrual, however, subjects continue to be followed for safety and the secondary endpoints of distant failure and survival. Endpoints in this trial include time to biochemical failure, PSA doubling time, safety, time to distant failure, and overall survival.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec11">
            <Heading>Safety and Tolerability</Heading>
            <Para TextBreak="No">In phase I/II studies of sipuleucel-T, the maximum tolerated dose was not reached. The most common adverse events, reported in patients in the sipuleucel-T group at a rate ≥ 15%, were chills, fatigue, fever, back pain, nausea, joint ache, and headache [<CitationRef CitationID="CR23_28">23</CitationRef>]. In 67.4% of patients in the sipuleucel-T group, these adverse events were mild or moderate in severity. Severe (Grade 3) and life-threatening (Grade 4) adverse events were reported in 23.6% and 4.0% of patients in the sipuleucel-T group compared with 25.1% and 3.3% of patients in the control group. Fatal (Grade 5) adverse events were reported in 3.3% of patients in the sipuleucel-T group compared with 3.6% of patients in the control group. The most common (≥ 2%) Grade 3–5 adverse events reported in the sipuleucel-T group were back pain and chills. Cerebrovascular events occurred in 3.5% of patients in the sipuleucel-T group compared to 2.6% of patients in the control group.</Para>
          </Section1>
          <Section1 ID="Sec12">
            <Heading>Discussion</Heading>
            <Para TextBreak="No">The approach to the patient with metastatic CRPC with no or minimal symptoms remains individualized. Although docetaxel confers a modest survival benefit, it can be associated with significant toxicities. Physicians and patients are often reluctant to proceed with chemotherapy despite the known survival benefit and therefore second-line hormonal manipulations are often used in this setting. Although PSA and some objective responses to second-line hormonal therapy have been reported, there is no evidence that survival is improved.</Para>
            <Para TextBreak="No">With FDA approval of sipuleucel-T approval, patients with no or minimal symptoms now have a therapeutic option that can prolong survival, is of short duration and low toxicity. Because the PSA does not usually decline nor do the imaging studies improve following treatment with sipulecuel-T, it may be difficult to determine whether an individual patient is benefiting from treatment with sipuleucel-T. With the development of improved biologic markers, it may become possible to better define those who are most likely to benefit from sipuleucel-T. At the present time, physicians should proceed with subsequent therapy appropriate for the patient’s clinical condition, following treatment with sipuleucel-T. Currently available data suggests that administration of sipulecuel-T does not preclude subsequent chemotherapy [<CitationRef CitationID="CR22_28">22</CitationRef>, <CitationRef CitationID="CR23_28">23</CitationRef>]. As sipuleucel-T is prescribed outside the clinical trial setting, there will be new lessons to be learned from the administration of immunotherapy in this population of prostate cancer patients. At one time, there was little enthusiasm for immunotherapy of solid tumors, and even less belief that such approaches would be beneficial in patients with metastatic disease. However, the results from the clinical trials of sipuleucel-T and other immunotherapeutic agents may change this paradigm. Results of the P-11 phase III trial of ADT induction followed by sipuleucel-T vs. control in men with hormone-sensitive biochemical relapse after prostatectomy will inform future studies in patients with low volume disease or those earlier in the natural history of the disease. In addition, sipuleucel-T may be of use in combination or in sequence with other active agents, as suggested by the pilot study combining sipuleucel-T with bevacizumab [<CitationRef CitationID="CR21_28">21</CitationRef>].</Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-829-4_Chapter_28.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1_28">
              <CitationNumber>1</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Jemal</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Siegel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Ward</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Murray</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Xu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Thun</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Cancer statistics, 2007</ArticleTitle>
                <JournalTitle>CA Cancer J Clin</JournalTitle>
                <VolumeID>57</VolumeID>
                <FirstPage>43</FirstPage>
                <LastPage>66</LastPage>
                <Occurrence Type="PID">
                  <Handle>17237035</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.3322/canjclin.57.1.43</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2009;59:225–49.</BibUnstructured>
            </Citation>
            <Citation ID="CR2_28">
              <CitationNumber>2</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MS</Initials>
                  <FamilyName>Cookson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Aus</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AL</Initials>
                  <FamilyName>Burnett</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>177</VolumeID>
                <FirstPage>540</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>17222629</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.juro.2006.10.097</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhs1Wmu7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007;177:540–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR3_28">
              <CitationNumber>3</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Dagher</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Abraham</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Rahman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Sridhara</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Pazdur</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>10</VolumeID>
                <FirstPage>8147</FirstPage>
                <LastPage>51</LastPage>
                <Occurrence Type="PID">
                  <Handle>15623588</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-04-1402</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhtFGjsrrE</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dagher R, Li N, Abraham S, Rahman A, Sridhara R, Pazdur R. Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Clin Cancer Res 2004;10:8147–51.</BibUnstructured>
            </Citation>
            <Citation ID="CR4_28">
              <CitationNumber>4</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IF</Initials>
                  <FamilyName>Tannock</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Wit</FamilyName>
                  <Particle>de</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WR</Initials>
                  <FamilyName>Berry</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>351</VolumeID>
                <FirstPage>1502</FirstPage>
                <LastPage>12</LastPage>
                <Occurrence Type="PID">
                  <Handle>15470213</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMoa040720</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXot1Kmu7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–12.</BibUnstructured>
            </Citation>
            <Citation ID="CR5_28">
              <CitationNumber>5</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Tangen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MH</Initials>
                  <FamilyName>Hussain</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>351</VolumeID>
                <FirstPage>1513</FirstPage>
                <LastPage>20</LastPage>
                <Occurrence Type="PID">
                  <Handle>15470214</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMoa041318</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXot1Kmu7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–20.</BibUnstructured>
            </Citation>
            <Citation ID="CR6_28">
              <CitationNumber>6</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DR</Initials>
                  <FamilyName>Berthold</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Pond</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>DeWit</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Eisenberger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IF</Initials>
                  <FamilyName>Tannock</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival of the TAX 327 study</ArticleTitle>
                <JournalTitle>ASCO Meeting Abstr</JournalTitle>
                <VolumeID>25</VolumeID>
                <FirstPage>50058</FirstPage>
              </BibArticle>
              <BibUnstructured>Berthold DR, Pond G, DeWit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival of the TAX 327 study. ASCO Meeting Abstr 2007;25:50058.</BibUnstructured>
            </Citation>
            <Citation ID="CR7_28">
              <CitationNumber>7</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TN</Initials>
                  <FamilyName>Kirk</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Moyad</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">National survey of advanced prostate cancer patients reveals disparity between perceptions and reality of treatment</ArticleTitle>
                <JournalTitle>J Clin Oncol (Meeting Abstracts)</JournalTitle>
                <VolumeID>24</VolumeID>
                <FirstPage>8590</FirstPage>
              </BibArticle>
              <BibUnstructured>Kirk TN, Moyad MA. National survey of advanced prostate cancer patients reveals disparity between perceptions and reality of treatment. J Clin Oncol (Meeting Abstracts) 2006;24:8590.</BibUnstructured>
            </Citation>
            <Citation ID="CR8_28">
              <CitationNumber>8</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DG</Initials>
                  <FamilyName>McNeel</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Prostate cancer antigens and vaccines, preclinical developments</ArticleTitle>
                <JournalTitle>Cancer Chemother Biol Response Modif</JournalTitle>
                <VolumeID>22</VolumeID>
                <FirstPage>247</FirstPage>
                <LastPage>61</LastPage>
                <Occurrence Type="PID">
                  <Handle>16110615</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0921-4410(04)22011-7</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXmtFKmtLo%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Drake, CG. Prostate cancer as a model for tumour immunotherapy. Nature Rev Immunol 2010;10:580–93.</BibUnstructured>
            </Citation>
            <Citation ID="CR9_28">
              <CitationNumber>9</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EJ</Initials>
                  <FamilyName>Small</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PF</Initials>
                  <FamilyName>Schellhammer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CS</Initials>
                  <FamilyName>Higano</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>24</VolumeID>
                <FirstPage>3089</FirstPage>
                <LastPage>94</LastPage>
                <Occurrence Type="PID">
                  <Handle>16809734</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2005.04.5252</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XnslKhs7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089–94.</BibUnstructured>
            </Citation>
            <Citation ID="CR10_28">
              <CitationNumber>10</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Haines</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SE</Initials>
                  <FamilyName>Larkin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AP</Initials>
                  <FamilyName>Richardson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RW</Initials>
                  <FamilyName>Stirling</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Heyderman</FamilyName>
                </BibAuthorName>
                <Year>1989</Year>
                <ArticleTitle Language="En">A novel hybridoma antibody (PASE/4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry</ArticleTitle>
                <JournalTitle>Br J Cancer</JournalTitle>
                <VolumeID>60</VolumeID>
                <FirstPage>887</FirstPage>
                <LastPage>92</LastPage>
                <Occurrence Type="PID">
                  <Handle>2605098</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/bjc.1989.385</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3cXhtFKqs7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Haines AM, Larkin SE, Richardson AP, Stirling RW, Heyderman E. A novel hybridoma antibody (PASE/4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry. Br J Cancer 1989;60:887–92.</BibUnstructured>
            </Citation>
            <Citation ID="CR11_28">
              <CitationNumber>11</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>NS</Initials>
                  <FamilyName>Goldstein</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores</ArticleTitle>
                <JournalTitle>Am J Clin Pathol</JournalTitle>
                <VolumeID>117</VolumeID>
                <FirstPage>471</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>11888088</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1309/G6PR-Y774-X738-FG2K</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol 2002;117:471–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR12_28">
              <CitationNumber>12</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>FH</Initials>
                  <FamilyName>Valone</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Small</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>MacKenzie</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Dendritic cell-based treatment of cancer: closing in on a cellular therapy</ArticleTitle>
                <JournalTitle>Cancer J</JournalTitle>
                <VolumeID>7</VolumeID>
                <IssueID>Suppl 2</IssueID>
                <FirstPage>S53</FirstPage>
                <LastPage>61</LastPage>
                <Occurrence Type="PID">
                  <Handle>11777265</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Valone FH, Small E, MacKenzie M, et al. Dendritic cell-based treatment of cancer: closing in on a cellular therapy. Cancer J 2001;7 Suppl 2:S53–61.</BibUnstructured>
            </Citation>
            <Citation ID="CR13_28">
              <CitationNumber>13</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Laus</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Yang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Ruegg</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Dendritic cell immunotherapy of prostate cancer: preclinical models and early clinical experience</ArticleTitle>
                <JournalTitle>Cancer Res Ther Control</JournalTitle>
                <VolumeID>11</VolumeID>
                <FirstPage>1</FirstPage>
                <LastPage>10</LastPage>
              </BibArticle>
              <BibUnstructured>Laus R, Yang D, Ruegg C. Dendritic cell immunotherapy of prostate cancer: preclinical models and early clinical experience. Cancer Res Ther Control 2001;11:1–10.</BibUnstructured>
            </Citation>
            <Citation ID="CR14_28">
              <CitationNumber>14</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EJ</Initials>
                  <FamilyName>Small</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Fratesi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DM</Initials>
                  <FamilyName>Reese</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>18</VolumeID>
                <FirstPage>3894</FirstPage>
                <LastPage>903</LastPage>
                <Occurrence Type="PID">
                  <Handle>11099318</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXptVSiurc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000;18:3894–903.</BibUnstructured>
            </Citation>
            <Citation ID="CR15_28">
              <CitationNumber>15</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SA</Initials>
                  <FamilyName>Rosenberg</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Shedding light on immunotherapy for cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>350</VolumeID>
                <FirstPage>1461</FirstPage>
                <LastPage>3</LastPage>
                <Occurrence Type="PID">
                  <Handle>15070799</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMcibr045001</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXivVagt70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rosenberg SA. Shedding light on immunotherapy for cancer. N Engl J Med 2004;350:1461–3.</BibUnstructured>
            </Citation>
            <Citation ID="CR16_28">
              <CitationNumber>16</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Zou</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Immunosuppressive networks in the tumour environment and their therapeutic relevance</ArticleTitle>
                <JournalTitle>Nat Rev Cancer</JournalTitle>
                <VolumeID>5</VolumeID>
                <FirstPage>263</FirstPage>
                <LastPage>74</LastPage>
                <Occurrence Type="PID">
                  <Handle>15776005</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nrc1586</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXivVars7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263–74.</BibUnstructured>
            </Citation>
            <Citation ID="CR17_28">
              <CitationNumber>17</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Takaue</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Tanosaki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Tobisu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Kakizoe</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Mizunuma</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Yanagida</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Kawai</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Antigen-pulsed dendritic cell therapy for the treatment of hormone-refractory prostate cancer: a phase I trial of APC8015</ArticleTitle>
                <JournalTitle>Proc ASCO</JournalTitle>
                <VolumeID>21</VolumeID>
                <FirstPage>1881</FirstPage>
              </BibArticle>
              <BibUnstructured>Takaue Y, Tanosaki R, Tobisu K, Kakizoe T, Mizunuma Y, Yanagida M, Kawai H. Antigen-pulsed dendritic cell therapy for the treatment of hormone-refractory prostate cancer: a phase I trial of APC8015. Proc ASCO 2002;21:1881.</BibUnstructured>
            </Citation>
            <Citation ID="CR18_28">
              <CitationNumber>18</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Burch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JK</Initials>
                  <FamilyName>Breen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JC</Initials>
                  <FamilyName>Buckner</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>6</VolumeID>
                <FirstPage>2175</FirstPage>
                <LastPage>82</LastPage>
                <Occurrence Type="PID">
                  <Handle>10873066</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXksVGhsr0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Burch PA, Breen JK, Buckner JC, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000;6:2175–82.</BibUnstructured>
            </Citation>
            <Citation ID="CR19_28">
              <CitationNumber>19</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Burch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GA</Initials>
                  <FamilyName>Croghan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DA</Initials>
                  <FamilyName>Gastineau</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>60</VolumeID>
                <FirstPage>197</FirstPage>
                <LastPage>204</LastPage>
                <Occurrence Type="PID">
                  <Handle>15176049</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.20040</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXntFGks78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Burch PA, Croghan GA, Gastineau DA, et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate 2004;60:197–204.</BibUnstructured>
            </Citation>
            <Citation ID="CR20_28">
              <CitationNumber>20</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Beinart</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BI</Initials>
                  <FamilyName>Rini</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Weinberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EJ</Initials>
                  <FamilyName>Small</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer</ArticleTitle>
                <JournalTitle>Clin Prostate Cancer</JournalTitle>
                <VolumeID>4</VolumeID>
                <FirstPage>55</FirstPage>
                <LastPage>60</LastPage>
                <Occurrence Type="PID">
                  <Handle>15992463</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.3816/CGC.2005.n.013</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXntVWqtbY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Beinart G, Rini BI, Weinberg V, Small EJ. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin Prostate Cancer 2005;4:55–60.</BibUnstructured>
            </Citation>
            <Citation ID="CR21_28">
              <CitationNumber>21</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BI</Initials>
                  <FamilyName>Rini</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Weinberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Fong</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Conry</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RM</Initials>
                  <FamilyName>Hershberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EJ</Initials>
                  <FamilyName>Small</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>107</VolumeID>
                <FirstPage>67</FirstPage>
                <LastPage>74</LastPage>
                <Occurrence Type="PID">
                  <Handle>16736512</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/cncr.21956</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XntVymu70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 2006;107:67–74.</BibUnstructured>
            </Citation>
            <Citation ID="CR22_28">
              <CitationNumber>22</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CS</Initials>
                  <FamilyName>Higano</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PF</Initials>
                  <FamilyName>Schellhammer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EJ</Initials>
                  <FamilyName>Small</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2009</Year>
                <ArticleTitle Language="En">Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>115</VolumeID>
                <FirstPage>3670</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>19536890</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/cncr.24429</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1MXhtVOnurbJ</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009;115:3670–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR23_28">
              <CitationNumber>23</CitationNumber>
              <BibUnstructured>Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. N Engl J Med 2010;363:411–422. doi: <ExternalRef><RefSource>10.1056/NEJMoa1001294</RefSource><RefTarget TargetType="DOI" Address="10.1056/NEJMoa1001294"/></ExternalRef>.</BibUnstructured>
            </Citation>
            <Citation ID="CR24_28">
              <CitationNumber>24</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Beer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GT</Initials>
                  <FamilyName>Bernstein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Corman</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Randomized trial of active cellular immunotherapy with sipuleucel-T in androgen dependent prostate cancer (ADPC)</ArticleTitle>
                <JournalTitle>J Clin Oncol (Meeting Abstracts)</JournalTitle>
                <VolumeID>25</VolumeID>
                <FirstPage>5059</FirstPage>
              </BibArticle>
              <BibUnstructured>Beer TM, Bernstein GT, Corman JM, et al. Randomized trial of active cellular immunotherapy with sipuleucel-T in androgen dependent prostate cancer (ADPC). J Clin Oncol (Meeting Abstracts) 2007;25:5059.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Part>
  </Book>
</Publisher>
